Genetics of spinal muscular atrophy

Czech version

Authors: P. Hedvičáková
Authors‘ workplace: Ústav biologie a lékařské genetiky 2. LF UK a FN Motol
Published in: Cesk Slov Neurol N 2020; 83/116(Supplementum 2): 17-20
doi: https://doi.org/10.48095/cccsnn20202S17

Overview

Spinal muscular atrophy (SMA) is a severe genetic disorder. The most frequent form of SMA is inherited in an autosomal recessive mode, caused by a homozygous deletion of a part of the SMN1 gene on the long arm of chromosome 5. Having frequency of carriers in Caucasian population about 1 : 40, it is the second most common autosomal recessive disease of childhood. The causal SMN1 gene was found in 1995. Since then, investigation of the number of copies of this gene has been performed by different techniques, the gold standard now being a multiplex ligation-dependent probe amplification. To predict the development of the disease, it is crucial to determine the number of SMN2 gene (so called pseudogene) copies, too. The patient’s phenotype is also impacted by other modification factors. Clinical genetics offers counselling to the families and, in relevant cases, recommends carrier testing. With the arrival of treatment possibilities in early stages of the disease, the prompt and early diagnostics has become essential.

Keywords:

spinal muscular atrophy – SMN1 gene – SMN2 gene – copy numbers – homozygous deletion – multiplex ligation-dependent probe amplification – carriers

Sources

1. Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 2015; 12(2): 290–302. doi: 10.1007/ s13311-014-0314-x.

2. Lefebvre S, Bürglen L, Reboullet S et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80(1): 155–165. doi: 10.1016/ 0092-8674(95)90460-3.

3. Bürglen L, Lefebvre S, Clermon O et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996; 32(3): 479–482. doi: 10.1006/ geno.1996.0147.

4. Rochette CF, Gilbert N, Simard LR. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet 2001; 108(3): 255–266. doi: 10.1007/ s004390100473.

5. Wirth B, Garbes L, Riessland M. How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. Curr Opin Genet Dev 2013; 23(3): 330–338. doi: 10.1016/ j.gde.2013.03.003.

6. Vondráček P, Zapletalová E, Ošlejšková H et al. Ovlivnění exprese mRNA genu SMN2 inhibitory histonových deacetyláz a jejich vliv na fenotyp spinální svalové atrofie I. a II. typu. Ceskl Slov Neurol N 2007; 70/ 103(4): 413–418.

7. Oprea GE, Kröber S, McWhorter ML et al. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008; 320(5875): 524–527. doi: 10.1126/ science.1155085.

8. Hauke J, Riessland M, Lunka S et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet 2009; 18(2): 304–317. doi: 10.1093/ hmg/ ddn357.

9. Bernal S, Alías L, Barceló MJ et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet 2010; 47(9): 640–642. doi: 10.1136/ jmg.2010.079004.

10. Calucho M, Bernal S, Alías L et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 2018; 28(3): 208–215. doi: 10.1016/ j.nmd.2018.01.003.

11. Van Der Steege G, Grootscholten PM, Cobben JM et al. Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5. Am J Hum Genet 1996; 59(4): 834–838.

12. Ogino S, Gao S, Leonard DG et al. Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet 2003; 11(3): 275–277. doi: 10.1038/ sj.ejhg.5200957.

13. Gambardella A, Mazzei R, Toscano A et al. Spinal muscular atrophy due to an isolated deletion of exon 8 of the telomeric survival motor neuron gene. Ann Neurol 1998; 44(5): 836–839. doi: 10.1002/ ana.410440522.

14. Maiti D, Bhattacharya M, Yadav S. Isolated exon 8 deletion in type 1 spinal muscular atrophy with bilateral optic atrophy: unusual genetic mutation leading to unusual manifestation? J Postgrad Med 2012; 58(4): 294–295. doi: 10.4103/ 0022-3859.105451.

15. Srivastava S, Mukherjee M, Panigrahi I et al. SMN2-deletion in childhood-onset spinal muscular atrophy. Am J Med Genet 2001; 101(3): 198–202. doi: 10.1002/ ajmg.1386.

16. Moulard B, Salachas F, Chassande B et al. Association between centromeric deletions of the SMN gene and sporadic adult-onset lower motor neuron disease. Ann Neurol 1998; 43(5): 640–644. doi: 10.1002/ ana.410430513.

17. Prior TW. Strategy for the molecular testing of spinal muscular atrophy. In: Prior TW. Spinal Muscular Atrophy. Cambridge, MA, USA: Academic Press 2017: 63–71.

18. Rudnik-Schöneborn S, Eggermann T, Kress W et al. Clinical utility gene card for: proximal spinal muscular atrophy (SMA) – update 2015. Eur J Hum Genet 2015; 23(11). doi: 10.1038/ ejhg.2015.90.

19. Fang P, Li L, Zeng J et al. Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls. BMC Musculoskelet Disord 2015; 16(1): 11. doi: 10.1186/ s12891-015-0457-x.

20. Cooper DS, Darki L, Beydoun SR. Spinal muscular atrophy – two case reports of compound heterozygosity. US Neurol 2019; 15(2): 97. doi: 10.17925/ usn.2019.15.2.97.

21. Wirth B, Schmidt T, Hahnen E et al. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet 1997; 61(5): 1102–1111. doi: 10.1086/ 301608.

22. Gonçalves-Rocha M, Oliveira J, Rodrigues L et al. New approaches in molecular diagnosis and population carrier screening for spinal muscular atrophy. Genet Test Mol Biomarkers 2011; 15(5): 319–326. doi: 10.1089/ gtmb.2010.0164.

23. Smith M, Calabro V, Chong B et al. Population screening and cascade testing for carriers of SMA. Eur J Hum Genet 2007; 15(7): 759–766. doi: 10.1038/ sj.ejhg.5201821.

24. Scheffer H, Cobben JM, Matthijs G et al. Best practice guidelines for molecular analysis in spinal muscular atrophy. Eur J Hum Genet 2001; 9(7): 484–491. doi: 10.1038/ sj.ejhg.5200667.

25. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med 2008; 11(11): 840–842. doi: 10.1097/ GIM.0b013e318188d069.

26. Hendrickson BC, Donohoe C, Akmaev VR et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet 2009; 46(9): 641–644. doi: 10.1136/ jmg.2009.066969.

27. Ogino S, Leonard DG, Rennert H et al. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 2002; 110(4): 301–307. doi: 10.1002/ ajmg.10425.

28. Verhaart IE, Robertson A, Wilson IJ et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. Orphanet J Rare Dis 2017; 12(1): 124. doi: 10.1186/ s13023-017-0671-8.

29. Hereditary Motor Syndromes, Spinal Muscular Atrophy. [online]. Available from URL: https:/ / neuromuscular.wustl.edu/ synmot.html#sma5q.